This session highlights norUDCA as an emerging bile acid therapy and its evolving role in the management of NAFLD. It explores the underlying mechanisms, clinical evidence, and potential benefits in improving liver inflammation and fibrosis. The discussion also focuses on patient selection, positioning in therapy, and how norUDCA may reshape future treatment strategies in fatty liver disease.